ATE110565T1 - Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten. - Google Patents

Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.

Info

Publication number
ATE110565T1
ATE110565T1 AT90915877T AT90915877T ATE110565T1 AT E110565 T1 ATE110565 T1 AT E110565T1 AT 90915877 T AT90915877 T AT 90915877T AT 90915877 T AT90915877 T AT 90915877T AT E110565 T1 ATE110565 T1 AT E110565T1
Authority
AT
Austria
Prior art keywords
spin
trapping
administration
methods
oxide
Prior art date
Application number
AT90915877T
Other languages
English (en)
Inventor
John M Carney
Robert A Floyd
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/422,651 external-priority patent/US5025032A/en
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE110565T1 publication Critical patent/ATE110565T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90915877T 1989-10-17 1990-10-17 Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten. ATE110565T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/422,651 US5025032A (en) 1989-10-17 1989-10-17 Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US58917790A 1990-09-27 1990-09-27

Publications (1)

Publication Number Publication Date
ATE110565T1 true ATE110565T1 (de) 1994-09-15

Family

ID=27025701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90915877T ATE110565T1 (de) 1989-10-17 1990-10-17 Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.

Country Status (12)

Country Link
US (4) US5405874A (de)
EP (1) EP0496796B1 (de)
JP (5) JP2620413B2 (de)
KR (1) KR960008230B1 (de)
AT (1) ATE110565T1 (de)
AU (4) AU653921B2 (de)
CA (1) CA2069961C (de)
DE (1) DE69012138T2 (de)
DK (1) DK0496796T3 (de)
ES (1) ES2044829T3 (de)
HK (1) HK1007281A1 (de)
WO (1) WO1991005552A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
WO1991005552A1 (en) * 1989-10-17 1991-05-02 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
CA2111836C (en) * 1991-06-18 2006-08-29 John M. Carney Spin-trapping pharmaceutical compositions and methods for use thereof
NZ244268A (en) * 1991-09-12 1994-09-27 Merrell Pharma Inc N-oxide quinoline derivatives and pharmaceutical compositions
US5292746A (en) * 1991-09-12 1994-03-08 Merrell Dow Pharmaceuticals Inc. Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
AU8051894A (en) * 1993-10-25 1995-05-22 Oklahoma Medical Research Foundation Novel phosphorus-containing spin-trap compositions
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
FR2731428B1 (fr) * 1995-03-06 1997-06-06 Centre Nat Rech Scient Derives phosphoryles de nitrones, leur procede de preparation et compositions les contenant
JPH11512427A (ja) * 1995-09-11 1999-10-26 ヘキスト・マリオン・ルセル・インコーポレイテツド 環状ニトロンおよびこれらを含有する医薬組成物
DE69636795D1 (de) * 1995-11-17 2007-02-08 Florida Internat University Azulenylnitrone als radikal fanger (spin trapping agents), verfahren zu ihrer herstellung und ihre anwendung
CA2251800A1 (en) * 1996-04-17 1997-10-23 Oklahoma Medical Research Foundation Nitrone free radical trap treatment of dementia associated with aids virus (hiv-1) infection
NZ332561A (en) * 1996-04-23 2001-01-26 Centaur Pharmaceuticals Inc Compositions comprising a nitrone compound for use in treating ocular inflammation
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
KR20000067915A (ko) * 1996-07-19 2000-11-25 센토르 파마슈티칼스, 인크. 푸란 니트론 화합물
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
WO1999036415A1 (en) * 1998-01-16 1999-07-22 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
WO1999036420A1 (en) * 1998-01-16 1999-07-22 Centaur Pharmaceuticals, Inc. Thiophene nitrone compounds
RU2225392C2 (ru) * 1998-06-24 2004-03-10 Реновис, Инк. Альфа-арил-N-алкилнитроны, фармацевтические композиции (варианты), способ ингибирования нейродегенеративных заболеваний, способ лечения и способы профилактики (варианты)
JP2002520386A (ja) 1998-07-17 2002-07-09 セントアー ファーマシューティカルズ インコーポレイテッド 炎症を処置するためのα−（２−ヒドロキシフェニル）ニトロン化合物、α−（２−ヒドロキシフェニル）ニトロン化合物を含む薬学的組成物およびそれらの使用
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
US6339102B1 (en) * 1999-06-09 2002-01-15 The United States Of America As Represented By The Secretary Of The Army Method and composition for treating and preventing retinal damage
CA2404291A1 (en) * 2000-03-30 2001-10-11 Oklahoma Medical Research Foundation Butylnitrone containing compositons for inhibition of cancer development
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6835754B2 (en) 2001-01-08 2004-12-28 Renovis, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US6762322B1 (en) * 2002-12-20 2004-07-13 Goodyear Tire & Rubber Company Preparation of nitrone derivatives
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
US7125934B1 (en) 2005-06-28 2006-10-24 The Goodyear Tire & Rubber Company Functionalization of living rubbery polymers with nitrones
AU2007277193B2 (en) * 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
US8227517B2 (en) * 2008-02-12 2012-07-24 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
WO2009110585A1 (ja) * 2008-03-07 2009-09-11 国立大学法人熊本大学 電子スピン共鳴測定用試料溶液及びその乾固物，並びにそれらを用いた測定方法
RU2538562C2 (ru) * 2009-04-20 2015-01-10 Вольво Констракшн Эквипмент Аб Интегрированная система для укладки дорожного покрытия
US9034926B2 (en) 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
ES2395803B1 (es) * 2011-08-01 2013-12-19 Consejo Superior De Investigaciones Científicas (Csic) - 80% Quinolilnitronas
DE102011088787A1 (de) 2011-12-16 2013-06-20 Evonik Industries Ag Siloxannitrone und deren Anwendung
WO2022169642A1 (en) * 2021-02-08 2022-08-11 Oklahoma Medical Research Foundation Okn-007 as a therapeutic agent for neurodegenerative diseases
DE102023124443A1 (de) * 2023-09-11 2025-03-27 Albert-Ludwigs-Universität Freiburg, Körperschaft des öffentlichen Rechts Vorrichtung zur Modifikation von Blut

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273702C (de) *
US35213A (en) * 1862-05-13 Improved hydrant
US35112A (en) * 1862-04-29 Improvement in head-rests for car-seats
US3396027A (en) * 1964-05-13 1968-08-06 Eastman Kodak Co Method of noodling gelatin dispersions
US3365296A (en) 1964-05-18 1968-01-23 Gen Aniline & Film Corp Light-sensitive ultraviolet absorbing compounds and diazotype materials containing the same
US3296145A (en) * 1965-10-21 1967-01-03 Millmaster Onyx Corp Quaternary ammonium-tertiary amine oxide compositions
US3775122A (en) 1967-07-28 1973-11-27 American Can Co Image production using photosensitive compositions of nitrone which is heat developed
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US3849934A (en) * 1971-05-03 1974-11-26 Scm Corp Alpha-aryl-n-lower alkyl nitrone-containing compositions useful as anti-fungal agents
US3767818A (en) 1971-05-03 1973-10-23 Scm Corp Phenyl nitrone containing compositions useful as anti microbial agents
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
GB1588417A (en) * 1977-03-15 1981-04-23 Agfa Gevaert Photoresist materials
US4224340A (en) * 1977-10-06 1980-09-23 William H. Rorer, Inc. Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
US4214003A (en) * 1977-10-06 1980-07-22 William H. Rorer, Inc. Method of treatment
US4197314A (en) * 1977-10-06 1980-04-08 William H. Rorer, Inc. Method of treating inflammation
US4870002A (en) * 1981-04-07 1989-09-26 The United States Of America As Represented By The Secretary Of The Air Force Method of prevention of oxidative injury to cells
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
WO1988005653A1 (en) * 1987-01-28 1988-08-11 Proctor Peter H Topical composition for stimulating hair growth with stable free radicals
USRE35213E (en) 1989-10-17 1996-04-16 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
WO1991005552A1 (en) * 1989-10-17 1991-05-02 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
EP0496796B1 (de) 1994-08-31
JP2620413B2 (ja) 1997-06-11
KR960008230B1 (ko) 1996-06-21
JP2816326B2 (ja) 1998-10-27
CA2069961C (en) 2000-05-02
AU653921B2 (en) 1994-10-20
EP0496796A1 (de) 1992-08-05
JPH10259128A (ja) 1998-09-29
AU710342B2 (en) 1999-09-16
DE69012138D1 (de) 1994-10-06
AU6613390A (en) 1991-05-16
AU8310198A (en) 1998-12-24
US6107315A (en) 2000-08-22
DE69012138T2 (de) 1995-04-06
US5405874A (en) 1995-04-11
JP2975587B2 (ja) 1999-11-10
WO1991005552A1 (en) 1991-05-02
DK0496796T3 (da) 1994-10-03
KR920702220A (ko) 1992-09-03
JPH0925263A (ja) 1997-01-28
ES2044829T3 (es) 1995-01-16
AU1131595A (en) 1995-03-23
AU710341B2 (en) 1999-09-16
AU8310298A (en) 1998-10-22
US5578617A (en) 1996-11-26
AU692197B2 (en) 1998-06-04
US5681965A (en) 1997-10-28
JP2002179563A (ja) 2002-06-26
ES2044829T1 (es) 1994-01-16
HK1007281A1 (en) 1999-04-09
JPH05505792A (ja) 1993-08-26
JPH10259178A (ja) 1998-09-29
CA2069961A1 (en) 1991-04-18

Similar Documents

Publication Publication Date Title
ATE110565T1 (de) Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
NO882732L (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
FR2612187B1 (fr) Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
NO884625D0 (no) N-substituerte derivater av 1-desoksynojirimycin og 1-desoksymannojirimycin, fremgangsmaate for deres fremstilling og deres anvendelse i legemiddel.
KR910700048A (ko) 오메프라졸의 항균제로서의 용도
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
DE3787377D1 (de) Eindringungserhöhende mittel zur transdermalen verabreichung systemischer mittel.
NO904378D0 (no) Fremgangsmaate for fremstilling av et modifisert protein for terapeutisk anvendelse.
DE69232323D1 (de) Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DE68904922D1 (de) Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.
ATA95989A (de) Pyridoncarbonsäurederivate und salze hievon, verfahren zur herstellung derselben und antibakterielle mittel, welche diese enthalten
DK393188A (da) Farmaceutisk praeparat til intranasal administrering
DE3878313D1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
DE68923151D1 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
IL85228A (en) 1-(4-hydroxy-3,5-di-tert.- butylbenzoyl) homopiperazine, various derivatives thereof, processes for the preparation of these and pharmaceutical compositions containing them
DE58904722D1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
EE04551B1 (et) Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
DE69125940D1 (de) Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
NO893256D0 (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
DE60024969D1 (de) 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee